ES2247959T1 - Formulacion medica en aerosol estabilizada en agua. - Google Patents

Formulacion medica en aerosol estabilizada en agua.

Info

Publication number
ES2247959T1
ES2247959T1 ES03754425T ES03754425T ES2247959T1 ES 2247959 T1 ES2247959 T1 ES 2247959T1 ES 03754425 T ES03754425 T ES 03754425T ES 03754425 T ES03754425 T ES 03754425T ES 2247959 T1 ES2247959 T1 ES 2247959T1
Authority
ES
Spain
Prior art keywords
formulation
formulation according
weight
parts
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES03754425T
Other languages
English (en)
Spanish (es)
Inventor
Akwete Adjei
Anthony Cutie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kos Life Sciences Inc
Original Assignee
Kos Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kos Life Sciences Inc filed Critical Kos Life Sciences Inc
Publication of ES2247959T1 publication Critical patent/ES2247959T1/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
ES03754425T 2002-09-03 2003-09-03 Formulacion medica en aerosol estabilizada en agua. Pending ES2247959T1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/234,825 US7074388B2 (en) 1998-12-10 2002-09-03 Water stabilized medicinal aerosol formulation
US234825 2002-09-03

Publications (1)

Publication Number Publication Date
ES2247959T1 true ES2247959T1 (es) 2006-03-16

Family

ID=31977472

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03754425T Pending ES2247959T1 (es) 2002-09-03 2003-09-03 Formulacion medica en aerosol estabilizada en agua.

Country Status (9)

Country Link
US (1) US7074388B2 (enExample)
EP (1) EP1569617A4 (enExample)
JP (1) JP2006502160A (enExample)
AU (1) AU2003272251A1 (enExample)
CA (1) CA2497171C (enExample)
DE (1) DE03754425T1 (enExample)
ES (1) ES2247959T1 (enExample)
MX (1) MXPA05002337A (enExample)
WO (1) WO2004022035A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60133203T3 (de) * 2000-07-31 2012-02-23 Nycomed Danmark Aps Fentanyl Zusammensetzung für nasale Anwendung
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
ME00420B (me) * 2003-03-20 2011-12-20 Boehringer Ingelheim Pharmaceuticals Inc Formulacija, za inhalator u kojem se odmjerava doza, u kojoj se kao propelenti koriste hidro-fluoro-alkani
RU2364400C2 (ru) * 2003-04-14 2009-08-20 Вектура Лтд Фармацевтические композиции
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
AR041873A1 (es) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
EP2211956A4 (en) 2007-10-10 2014-07-09 Parion Sciences Inc DISPOSAL OF OSMOLYTES WITH A NOSE CANNULA
EP2477601B1 (en) * 2009-09-15 2017-09-13 Union Carbide Chemicals & Plastics Technology LLC Personal care compositions with ethylene acrylic acid copolymer aqueous dispersions
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
US8986663B2 (en) 2010-11-04 2015-03-24 Rohm And Haas Company Skin care compositions
US8778383B2 (en) 2011-06-07 2014-07-15 Parion Sciences, Inc. Methods of treatment
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
CA2938994A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Inhalable formulations of sodium cromolyn with improved bioavailability
CN106535889A (zh) 2014-02-10 2017-03-22 帕塔拉制药有限责任公司 用于治疗肺疾病的肥大细胞稳定剂
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
EP3506893A4 (en) 2016-08-31 2020-01-22 Respivant Sciences GmbH CROMOLYN COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONAL FIBROSIS
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
SG11202012005VA (en) 2018-06-08 2021-01-28 Toko Yakuhin Kogyo Co Ltd Fluticasone furoate nasal preparation composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
DE4446891A1 (de) * 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
US6458338B1 (en) * 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
DE19847969A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
US6261539B1 (en) * 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
US6540983B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6447750B1 (en) * 2000-05-01 2002-09-10 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6565833B1 (en) * 2000-05-01 2003-05-20 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6548049B1 (en) * 2000-05-01 2003-04-15 Aeropharm Technology Incorporated Medicinal aerosol formulation

Also Published As

Publication number Publication date
US20030091512A1 (en) 2003-05-15
AU2003272251A1 (en) 2004-03-29
WO2004022035A1 (en) 2004-03-18
EP1569617A4 (en) 2010-10-27
JP2006502160A (ja) 2006-01-19
MXPA05002337A (es) 2005-12-05
US7074388B2 (en) 2006-07-11
CA2497171C (en) 2009-04-28
CA2497171A1 (en) 2004-03-18
EP1569617A1 (en) 2005-09-07
DE03754425T1 (de) 2006-03-09

Similar Documents

Publication Publication Date Title
EP2010190B1 (en) Pharmaceutical solution formulations for pressurised metered dose inhalers
US6261539B1 (en) Medicinal aerosol formulation
DE03754425T1 (de) Anwendungen die in Bezug stehen mit durch Wasser stabilisierte medizinische Aerosolformulierungen
US20130074834A1 (en) Pharmaceutical Combinations
JP2006502160A5 (enExample)
SK92494A3 (en) Pharmaceutical agent
JP2024525555A5 (enExample)
DK2727582T3 (en) Pharmaceutical aerosol formulations of formoterol and beclomethasone dipropionate
AU2012300082B2 (en) Method for preparing metered dose sprayed inhaler for treating respiratory disease
ES2317306T3 (es) Procedimiento para la preparacion de formulaciones en aerosol en suspension, en el que las particulas se forman por precipitacion dentro de un frasco de aerosol.
WO2002007672A2 (en) A medicinal aerosol formulation
US9241904B1 (en) Method for preparing metered dose sprayed inhaler for treating respiratory disease
WO2002015883A1 (en) A method of stabilizing a dry powder pharmaceutical formulation
HK1176550A (en) The preparation for formulation composition and manufacturing processes of metered does inhalers treated respiratory diseases
HK1176550B (en) The preparation for formulation composition and manufacturing processes of metered does inhalers treated respiratory diseases
TW202600124A (zh) 一種吸入性醫藥製劑、裝置及其用途
MXPA01005716A (en) A medicinal aerosol formulation
NZ621362B2 (en) Method for preparing metered dose sprayed inhaler for treating respiratory disease
EA039998B1 (ru) Способ уменьшения частоты обострений хобл умеренной/тяжелой хобл степени
HK1128615A (en) Pharmaceutical solution formulations for pressurised metered dose inhalers
AU2007231727A1 (en) Water stabilized medicinal aerosol formulation
HK1181310A (en) Pharmaceutical solution formulations for pressurised metered dose inhalers